Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Investigators at University of Munich release new data on breast cancer
April 23rd, 2009
"Overexpression of Her-2/neu-oncoprotein is used as marker for HerceptinA (R) therapy. To investigate the sensitivity and specificity of automatic immunohistochemistry (Benchmark, Ventana), we compared the results to the manual testing (Dako) in 130 breast carcinomas and validated the results by fluorescence in situ hybridization (FISH)," scientists in Munich, Germany report. "Manual and automatic immunohistochemistry of Her-2/neu-oncoprotein using two different antibodies (HercepTest (TM), Her-2/neuTest 4B5) was analyzed. FISH was performed in all cases with uncertain or strong overexpression in either immunohistochemical stainings or with different immunohistochemical...
Source: Women's Health Weekly (2009-04-23)
|
